Secondary Outcome(s)
|
Absolute Change in Body Mass Index (BMI)
[Time Frame: From Baseline at Week 24]
|
Absolute Change in BMI Z-score for Participants <=20 Years of Age at Baseline
[Time Frame: From Baseline at Week 24]
|
Number of Pulmonary Exacerbations (PEx)
[Time Frame: From Baseline through Week 24]
|
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
[Time Frame: From Baseline through Week 24]
|
Absolute Change in Sweat Chloride
[Time Frame: From Baseline at Week 4]
|
Time-to-first Pulmonary Exacerbation (PEx)
[Time Frame: From Baseline through Week 24]
|
Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score
[Time Frame: From Baseline at Week 4]
|
Observed Pre-dose Concentration (Ctrough) of VX-445, TEZ, M1-TEZ, and IVA
[Time Frame: Pre-dose on Week 4, 8, 12, and 16]
|
Absolute Change in Sweat Chloride (SwCl)
[Time Frame: From Baseline through Week 24]
|
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
[Time Frame: From first dose of study drug in TC treatment period up to 28 days after last dose of study drug or to the completion of study participation date, whichever occurs first (up to 28 weeks)]
|
Absolute Change in Body Weight
[Time Frame: From Baseline at Week 24]
|
Absolute Change in Cystic Fibrosis Questionnaire Revised (CFQ-R) Respiratory Domain Score
[Time Frame: From Baseline through Week 24]
|